BR9915011A - Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto - Google Patents
Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um compostoInfo
- Publication number
- BR9915011A BR9915011A BR9915011-5A BR9915011A BR9915011A BR 9915011 A BR9915011 A BR 9915011A BR 9915011 A BR9915011 A BR 9915011A BR 9915011 A BR9915011 A BR 9915011A
- Authority
- BR
- Brazil
- Prior art keywords
- suffering
- alkyl
- compounds
- cox
- human
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101150071146 COX2 gene Proteins 0.000 title 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 title 1
- 101150000187 PTGS2 gene Proteins 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 229940111134 coxibs Drugs 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSTOS, MéTODO PARA A PREPARAçãO DOS MESMOS, COMPOSIçãO FARMACêUTICA, MéTODOS DE TRATAMENTO DE UM INDIVìDUO HUMANO OU ANIMAL SOFRENDO DE UMA CONDIçãO QUE é MEDIADA PELA INIBIçãO SELETIVA DE COX-2 E SOFRENDO DE UM DISTúRBIO INFLAMATóRIO, E, USO DE UM COMPOSTO" A invenção proporciona os compostos de fórmula (I) e seus derivados farmaceuticamente aceitáveis nos quais: R^ 0^ e R¹ são independentemente selecionados de H, halogênio, C~ 1-6~-alquila, C~ 1-6~-alcoxila, ou C~ 1-6~-alcoxila substituída com um ou mais átomos de flúor; R² é H, C~ 1-6~-alquila, C~ 1-6~-alquila substituída com um ou mais átomos de flúor, C~ 1-6~-alcoxila, C~ 1-6~-hidróxi-alquila, SC~ 1-6~-alquila, C(O)H, C(O)C~ 1-6~-alquila, C~ 1-6~-alquil-sulfonila, C~ 1-6~-alcoxila substituída com um ou mais átomos de flúor; e R³ é C~ 1-6~-alquila ou NH~ 2~. Os compostos de fórmula (I) são inibidores potentes e seletivos de COX-2 e são utilizados no tratamento de dor, de febre, de inflamação ou de uma variedade de condições e de doenças.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9824062.5A GB9824062D0 (en) | 1998-11-03 | 1998-11-03 | Chemical compounds |
| GBGB9920909.0A GB9920909D0 (en) | 1999-09-03 | 1999-09-03 | Chemical compounds |
| PCT/EP1999/008186 WO2000026216A1 (en) | 1998-11-03 | 1999-11-01 | Pyrazolopyridine derivatives as selective cox-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9915011A true BR9915011A (pt) | 2001-08-07 |
Family
ID=26314603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9915011-5A BR9915011A (pt) | 1998-11-03 | 1999-11-01 | Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7223772B1 (pt) |
| EP (1) | EP1127058B1 (pt) |
| JP (1) | JP3420751B2 (pt) |
| KR (1) | KR20010075673A (pt) |
| CN (1) | CN1263755C (pt) |
| AR (1) | AR021055A1 (pt) |
| AT (1) | ATE275148T1 (pt) |
| AU (1) | AU767464B2 (pt) |
| BR (1) | BR9915011A (pt) |
| CA (1) | CA2349567A1 (pt) |
| CO (1) | CO5150164A1 (pt) |
| CZ (1) | CZ20011556A3 (pt) |
| DE (1) | DE69919887T2 (pt) |
| ES (1) | ES2228127T3 (pt) |
| GC (1) | GC0000112A (pt) |
| HU (1) | HUP0104204A3 (pt) |
| MY (1) | MY119689A (pt) |
| NO (1) | NO318884B1 (pt) |
| NZ (1) | NZ511349A (pt) |
| PE (1) | PE20001305A1 (pt) |
| PL (1) | PL348208A1 (pt) |
| TR (1) | TR200101208T2 (pt) |
| TW (1) | TW542836B (pt) |
| WO (1) | WO2000026216A1 (pt) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5190664A1 (es) | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 |
| US7172769B2 (en) | 1999-12-08 | 2007-02-06 | Pharmacia Corporation | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| GB0002312D0 (en) * | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
| PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| DE60112609T2 (de) | 2000-12-15 | 2006-01-19 | Glaxo Group Ltd., Greenford | Pyrazolopyridine |
| JP2004515550A (ja) | 2000-12-15 | 2004-05-27 | グラクソ グループ リミテッド | 治療用化合物 |
| WO2002072581A2 (en) | 2001-03-08 | 2002-09-19 | Smithkline Beecham Corporation | Pyrazolopyriadine derivatives |
| EP1372643A1 (en) | 2001-03-30 | 2004-01-02 | Smithkline Beecham Corporation | Pyrazolopyridines, process for their preparation and use as therapeutic compounds |
| DE60212949T2 (de) | 2001-04-10 | 2007-01-04 | Smithkline Beecham Corp. | Antivirale pyrazolopyridin verbindungen |
| US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
| EP1385847B1 (en) | 2001-04-27 | 2005-06-01 | SmithKline Beecham Corporation | Pyrazolo[1,5-a]pyridine derivatives |
| PL366827A1 (en) | 2001-06-21 | 2005-02-07 | Smithkline Beecham Corporation | Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
| ES2286272T3 (es) * | 2001-09-07 | 2007-12-01 | Smithkline Beecham Corporation | Pirizolo-piridinas para el tratamiento de infecciones por herpes. |
| ATE326466T1 (de) | 2001-10-05 | 2006-06-15 | Smithkline Beecham Corp | Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion |
| GB0124936D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124931D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| ES2292839T3 (es) | 2001-12-11 | 2008-03-16 | Smithkline Beecham Corporation | Derivados de pirazolo-piridina como agentes contra el herpes. |
| PL212910B1 (pl) | 2002-02-12 | 2012-12-31 | Smithkline Beecham Corp | Pochodna nikotynoamidu, srodek farmaceutyczny i zastosowanie pochodnej nikotynoamidu |
| US7235560B2 (en) | 2002-08-19 | 2007-06-26 | Glaxo Group Limited | Pyrimidine derivative as selective COX-2 inhibitors |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| WO2004033454A1 (en) | 2002-10-03 | 2004-04-22 | Smithkline Beecham Corporation | Therapeutic compounds based on pyrazolopyridine derivatives |
| WO2004076450A1 (en) | 2003-02-27 | 2004-09-10 | J. Uriach Y Compañia S.A. | Pyrazolopyridine derivates |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308201D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| WO2004098619A2 (en) | 2003-05-07 | 2004-11-18 | Osteologix A/S | Treating cartilage / bone conditions with water-soluble strontium salts |
| GB0318814D0 (en) | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| EA200801909A1 (ru) | 2004-12-23 | 2009-06-30 | Глэксо Груп Лимитед | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина |
| DE102005024012A1 (de) * | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln |
| EP2038279A2 (en) * | 2006-06-06 | 2009-03-25 | Avigen, Inc. | Substituted pyrazolo [1,5- alpha] pyridine compounds and their methods of use |
| US20100111858A1 (en) * | 2007-01-19 | 2010-05-06 | Howard Carol P | Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands |
| GB0704407D0 (en) | 2007-03-07 | 2007-04-18 | Glaxo Group Ltd | Compounds |
| US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| WO2011012622A1 (en) | 2009-07-30 | 2011-02-03 | Glaxo Group Limited | Benzoxazinone derivatives for the treatment of glytl mediated disorders |
| WO2011023753A1 (en) | 2009-08-27 | 2011-03-03 | Glaxo Group Limited | Benzoxazine derivatives as glycine transport inhibitors |
| GB201000685D0 (en) | 2010-01-15 | 2010-03-03 | Glaxo Group Ltd | Novel compounds |
| GB201007791D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel compounds |
| GB201007789D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel Compound |
| EP2590953B1 (en) | 2010-07-09 | 2014-10-29 | Convergence Pharmaceuticals Limited | Tetrazole compounds as calcium channel blockers |
| EP2665729B1 (en) | 2011-01-19 | 2015-04-01 | Convergence Pharmaceuticals Limited | Piperazine derivatives as cav2.2 calcium channel blockers |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| US20240165148A1 (en) | 2021-03-15 | 2024-05-23 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925849A (en) | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
| US5155114A (en) | 1989-01-23 | 1992-10-13 | Fujisawa Pharmaceutical Company, Ltd. | Method of treatment using pyrazolopyridine compound |
| GB8901423D0 (en) | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| JPH05503919A (ja) | 1989-06-13 | 1993-06-24 | スミスクライン・ビーチャム・コーポレイション | 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制 |
| AU622330B2 (en) | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
| WO1991019497A1 (en) | 1990-06-12 | 1991-12-26 | Smithkline Beecham Corporation | Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases |
| GB9015764D0 (en) | 1990-07-18 | 1990-09-05 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| US5300478A (en) | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
| KR19980703559A (ko) | 1995-04-04 | 1998-11-05 | 그레이엄브레레톤 | 이미다조［1,2-ａ］피리딘 유도체 |
| US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| EP0833664A1 (en) | 1995-06-12 | 1998-04-08 | G.D. SEARLE & CO. | Combination of a cyclooxygenase-2 inhibitor and a leukotriene b 4? receptor antagonist for the treatment of inflammations |
| ES2247604T3 (es) | 1995-06-12 | 2006-03-01 | G.D. SEARLE & CO. | Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa. |
| KR100382619B1 (ko) | 1997-09-05 | 2003-05-09 | 글락소 그룹 리미티드 | 2,3-디아릴-피라졸로[1,5-ｂ]피리다진 유도체, 그의 제조방법 및 시클로옥시게나제 2(ｃｏｘ-2) 억제제로서의 용도 |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| US6711762B2 (en) | 2002-01-30 | 2004-03-30 | Ktk Services, Inc. | Method of using a truck cab bridge bed |
-
1999
- 1999-11-01 JP JP2000579604A patent/JP3420751B2/ja not_active Expired - Fee Related
- 1999-11-01 CA CA002349567A patent/CA2349567A1/en not_active Abandoned
- 1999-11-01 EP EP99955897A patent/EP1127058B1/en not_active Expired - Lifetime
- 1999-11-01 AR ARP990105525A patent/AR021055A1/es unknown
- 1999-11-01 CN CNB99815234XA patent/CN1263755C/zh not_active Expired - Fee Related
- 1999-11-01 DE DE69919887T patent/DE69919887T2/de not_active Expired - Fee Related
- 1999-11-01 NZ NZ511349A patent/NZ511349A/en unknown
- 1999-11-01 TR TR2001/01208T patent/TR200101208T2/xx unknown
- 1999-11-01 BR BR9915011-5A patent/BR9915011A/pt not_active IP Right Cessation
- 1999-11-01 WO PCT/EP1999/008186 patent/WO2000026216A1/en not_active Ceased
- 1999-11-01 AT AT99955897T patent/ATE275148T1/de not_active IP Right Cessation
- 1999-11-01 HU HU0104204A patent/HUP0104204A3/hu unknown
- 1999-11-01 KR KR1020017005495A patent/KR20010075673A/ko not_active Ceased
- 1999-11-01 PL PL99348208A patent/PL348208A1/xx not_active Application Discontinuation
- 1999-11-01 CZ CZ20011556A patent/CZ20011556A3/cs unknown
- 1999-11-01 ES ES99955897T patent/ES2228127T3/es not_active Expired - Lifetime
- 1999-11-01 US US09/830,836 patent/US7223772B1/en not_active Expired - Fee Related
- 1999-11-01 AU AU12667/00A patent/AU767464B2/en not_active Ceased
- 1999-11-02 CO CO99068974A patent/CO5150164A1/es unknown
- 1999-11-02 GC GCP1999355 patent/GC0000112A/xx active
- 1999-11-02 TW TW088119040A patent/TW542836B/zh not_active IP Right Cessation
- 1999-11-02 MY MYPI99004739A patent/MY119689A/en unknown
- 1999-11-03 PE PE1999001103A patent/PE20001305A1/es not_active Application Discontinuation
-
2001
- 2001-05-02 NO NO20012156A patent/NO318884B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY119689A (en) | 2005-06-30 |
| TW542836B (en) | 2003-07-21 |
| NO20012156D0 (no) | 2001-05-02 |
| JP3420751B2 (ja) | 2003-06-30 |
| DE69919887D1 (de) | 2004-10-07 |
| NO20012156L (no) | 2001-07-02 |
| KR20010075673A (ko) | 2001-08-09 |
| NO318884B1 (no) | 2005-05-18 |
| JP2002528547A (ja) | 2002-09-03 |
| WO2000026216A1 (en) | 2000-05-11 |
| TR200101208T2 (tr) | 2001-10-22 |
| CA2349567A1 (en) | 2000-05-11 |
| ES2228127T3 (es) | 2005-04-01 |
| HUP0104204A2 (hu) | 2002-04-29 |
| ATE275148T1 (de) | 2004-09-15 |
| AU767464B2 (en) | 2003-11-13 |
| CN1263755C (zh) | 2006-07-12 |
| AU1266700A (en) | 2000-05-22 |
| AR021055A1 (es) | 2002-06-12 |
| CO5150164A1 (es) | 2002-04-29 |
| PE20001305A1 (es) | 2000-12-06 |
| CZ20011556A3 (cs) | 2001-11-14 |
| HUP0104204A3 (en) | 2002-06-28 |
| EP1127058A1 (en) | 2001-08-29 |
| GC0000112A (en) | 2005-06-29 |
| DE69919887T2 (de) | 2005-09-15 |
| EP1127058B1 (en) | 2004-09-01 |
| NZ511349A (en) | 2003-10-31 |
| US7223772B1 (en) | 2007-05-29 |
| PL348208A1 (en) | 2002-05-06 |
| CN1332741A (zh) | 2002-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9915011A (pt) | Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto | |
| BR9812046A (pt) | Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto | |
| BR0015193A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas | |
| EA200000723A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| BRPI0409417A (pt) | método para usar um composto, composto, e, composição | |
| BR0313718A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto | |
| BR0113448A (pt) | Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase | |
| BR0015821A (pt) | Derivados de pirimidina | |
| NO20033181L (no) | Substituerte alkylaminderivater og fremgangsmåter for anvendelse | |
| TR199701105T1 (xx) | �midazo (1,2-a)piridin t�revleri. | |
| EA200001223A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| YU56492A (sh) | Derivati hinuklidina | |
| BR9915420A (pt) | Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis | |
| EA200001224A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| BR9813973A (pt) | Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição. | |
| BRPI0407834A (pt) | composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase | |
| TR199900046T2 (xx) | Se�ici siklooksijenaz-2 inhibit�rleri olarak ikameli piridinler. | |
| EA200000759A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| BR0312020A (pt) | Método de tratamento de distúrbios, compostos, composições farmacêuticas, e, uso de um composto | |
| BRPI0416212A (pt) | derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação | |
| BR9806060A (pt) | Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina. | |
| BR9808953A (pt) | Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
| EA200200562A1 (ru) | Антагонисты аденозиновых рецепторов и способы их получения и использования |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA(S) 8A E 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009. |